Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease. Inside Beauty spoke to Jamie Sachs ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

Morgan Stanley began coverage on shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in a research report released on ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

New York, New York-- (Newsfile Corp. - February 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...